Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $85 from $96 and keeps a Buy rating on the shares. The company’s Q1 ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Shares of Viking Therapeutics (NASDAQ ... a VK2735 pill that would eliminate needles from the process, and that the company will have phase 2 data on that pill ready in the second quarter of ...